剑指KRAS“三代通吃”,小分子创新药黑马尽揽靶向治疗新红利

建国路128号
29 May

5月22日,国家药监局突然发力,一口气批了三款国产一类新药。大抵上是为即将来临的“6·30”关键节点提前做准备。在最近还算火热的创新药行业,市场对各种重磅数据、天价交易已经见怪不怪了,因此对于这种创新落地的新闻已经没多大感觉。但事实上,对于一些特殊品种,其商业化的获批意味着其“临床-商业化现金流-上市后再研究-治疗天花板提升”的飞轮即将启动。当日获批的加科思的戈来雷塞(KRAS G12C抑制剂)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10